01 — Question
Start with the patient biology.
Every programme begins with how neurodegenerative and autoimmune conditions actually present in people.
Preclinical neuroscience research
Pioneering Neuroscience: A Strategic Framework for Neural Regeneration.
Engineering clinical frameworks to intercept neurological disease at the cellular level.
- 03
- Research programmes
- P0–P2
- Current pipeline range
- 14
- Enquiry languages
- 100%
- Raw data shared
Our approach
- 01Question
- 02Model
- 03Measure
- 04Restore
02 — Model
Build faithful human models.
Patient-relevant neural cell systems let us test ideas before they reach a clinic.
03 — Measure
Quantify what changes.
Imaging, biomarkers and functional readouts turn observations into data we can defend.
04 — Restore
Aim for neurorestoration.
The long-term goal is to protect and rebuild neural function, not just slow its loss.
The framework
From reactive care to neural renewal
From reactive care to neural renewal
Most care for neurological disease treats symptoms, not causes. We study the cellular mechanisms behind that decline instead.
- Target the molecular pathology, not the symptom label
- Use the nervous system's own regenerative capacity
- Intercept disease progression at the cellular level
Decoding the brain's self-repair systems
Neural tissue can repair itself, until chronic disease exhausts those pathways. Our pipeline works on restoring them.
- Restore proteostatic integrity in stressed neurons
- Rebalance mitochondrial bioenergetics
- Clear senescent cells and reactivate neural stem cell niches
Translating discovery into clinical deliverables
Bench findings only matter if they scale. We build toward endpoints measured in function, not survival alone.
- Neurological healthspan as the primary endpoint
- Therapies that buffer against pathogenic stressors
- Recovery of functional independence
Redefining the limits of neurological resilience
Our long-term aim is simple to state: a neurological diagnosis should not decide what a person can do next.
- Turn regenerative models into real therapies
- Optimise the brain's own repair capacity
- Change the trajectory of neurological disease
Research programmes
Three programmes, one regenerative neuroscience thesis
Programme 01
Neural Cell Therapy
Active — discovery / preclinicalOur most active line of work, though not the whole of our research. We investigate engineered cell-therapy architectures adapted for neuroinflammatory and neurodegenerative disease, where the target is a pathogenic glial or immune cell population within the nervous system rather than a tumour. The programme is organised around construct design, safety modelling and neural mechanism readouts.
Cell engineering research
Construct design, transduction efficiency, and vector-free delivery approaches evaluated across donor-derived neural and immune co-cultures.
Safety and tolerability studies
Cytokine and neuroinflammatory release characterisation, on-target/off-tissue modelling, and engineered safety-switch evaluation in vitro.
Mechanism investigation
Single-cell readouts of neural-immune interaction, expansion, exhaustion and memory phenotype to explain why a construct behaves as it does.
Programme 02
Neurodiagnostics
Assay developmentTherapy decisions are only as good as the neural and immune picture behind them. We build high-dimensional profiling assays that describe a patient’s neurological and neuroimmune state with enough resolution to stratify who might respond to a given intervention.
Neural profiling
Multi-parameter cytometry and transcriptional panels covering neuronal, glial and neuroimmune compartments.
Biomarker discovery
Candidate markers of neural dysfunction validated across independent sample cohorts.
Patient stratification
Statistical models that group patients by mechanism rather than by symptom label alone.
Programme 03
Neurorestoration
ExploratoryFor patients whose nervous systems are depleted by disease or treatment, restoration is the goal rather than suppression. This programme studies how compromised neural compartments recover, and what can be done to accelerate that recovery safely.
Cell regeneration
Ex vivo expansion and differentiation protocols for depleted neural and supporting cell populations.
Function recovery
Functional assays that measure restored neural response, not just restored cell counts.
Neural enhancement
Adjunct strategies evaluated for durability and neuroinflammatory risk.
Inside the lab
A research organisation, and nothing else
Cytosomatic Labs does not treat patients, sell products or offer clinical services. Every hour of the week goes into preclinical neuroscience research: culture work, assay development, data review and method documentation.
Scientific standards
Data transparency, stated plainly
- 01
Study designs are documented before data collection begins.
- 02
Every key result is reproduced with an orthogonal method.
- 03
Negative and null results are recorded and retained.
- 04
External collaborators receive raw data, not only summaries.
Method in practice
Every experiment is run by people who read the raw data first
Our team works directly with the instruments, the cells and the datasets. There is no wall between the scientist designing the study and the scientist validating the result.
That closeness is what lets us catch subtle signals early, and what keeps our stage labels honest.
Our vision
Build the evidence first. Earn the therapy second.
We are an early-stage organization, and we describe ourselves that way deliberately. Our work today is preclinical: characterising neural dysfunction, validating targets, and building the assay infrastructure that any credible neuroscience programme requires.
Every claim we make is bounded by the data behind it. That discipline is the reason academic groups and clinical investigators choose to collaborate with us.
Research driven
Rigorous, reproducible scientific method.
Patient focused
Outcomes measured in restored function.
Common questions
What people ask about our research
- What does Cytosomatic Labs research?
- We are a neuroscience biotechnology lab running preclinical research in three areas — neural cell therapy, neurodiagnostics and neurorestoration — focused on neurodegenerative and autoimmune disease.
- What stage is the research at?
- Discovery and preclinical. We do not run clinical trials today. Programme stages are labelled on this page so collaborators know exactly what exists.
- Who do you collaborate with?
- Academic neuroscience groups, clinical investigators, translational funds, and instrument partners. Collaborators receive raw datasets and method files, not only summaries.
- Where is Cytosomatic Labs based?
- Toronto, Ontario, Canada. Research enquiries are handled in 14 languages through our contact page.
Knowledge Hub
Scientific deep dives, written by the team doing the work
Cellular repair
Cellular repair mechanisms in neurodegeneration
Proteostasis, mitochondrial quality control and neural stem-cell niches form the nervous system's repair capacity. This deep dive maps each system and the failure points our preclinical work targets.
Neurodiagnostics
Multi-parameter neurodiagnostics: building a resolvable picture
Single-analyte tests collapse heterogeneous biology into one number. High-dimensional panels recover the structure that stratification depends on — if the analysis is designed before the data is collected.
Neuroinflammation
Neuroinflammatory mechanisms in autoimmune neurology
Neuroinflammation is neither uniformly protective nor uniformly destructive. Its effect depends on cell state, duration and the integrity of the barriers around the compartment.
Collaborate with a lab that publishes its methods
We work with academic groups, clinical investigators, translational funds and instrument partners. Tell us where your neuroscience programme needs depth.